Heart Test Laboratories, Inc.

NasdaqCM HSCS

Heart Test Laboratories, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending October 31, 2024: -51,867.90%

Heart Test Laboratories, Inc. Net Income Margin is -51,867.90% for the Trailing 12 Months (TTM) ending October 31, 2024, a -43,292.50% change year over year. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

Heart Test Laboratories, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending October 31, 2023 was -119.53%, a 99.83% change year over year.
Heart Test Laboratories, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending October 31, 2022 was -68,605.32%.

Key data

Date	Net Income Margin	EBITDA Margin	EBIT Margin	EBITDA

NasdaqCM: HSCS

Heart Test Laboratories, Inc.

CEO	Mr. Andrew Simpson
IPO Date	June 16, 2022
Location	United States
Headquarters	550 Reserve Street
Employees	15
Sector	Health Care
Industries Medical Instruments Telehealth

Description

Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional 12-lead resting ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.

Key trends

Past 5 years